Catalyst
Slingshot members are tracking this event:
FDA approves Tesaro's (TSRO) ZEJULA (niraparib), a PARP inhibitor that treats adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TSRO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 27, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Zejula, Niraparib, Parp Inhibitor, Peritoneal, Fallopian Tube, Epithelial Ovarian, Cancer Treatment
